




^1H NMR of (4*R*,5*R*)-Dimethyl-2,2-dipropyl-1,3-dioxolane-4,5-dicarboxylate ((*R,R*)-**1b**) (CDCl_3)




^{13}C NMR of (*R,R*)-**1b** (CDCl_3)




IR spectrum of **(*R,R*)-1b**




¹H NMR of (*4R,5R*)-*N,N*-dimethoxy-*N,N*-dimethyl-2,2-dipropyl-1,3-dioxolane-4,5-dicarboxamide (**(*R,R*)-2b**) (CDCl₃)




¹³C NMR of (*R,R*)-2b (CDCl₃)




IR spectrum of (*R,R*)-2b




^1H NMR of 1,1'-((4*R*,5*R*)-2,2-dipropyl-1,3-dioxolane-4,5-diyl)diethanone ((*R,R*)-**3b**) (CDCl_3)




^{13}C NMR of (*R,R*)-**3b** (CDCl_3)




IR spectrum of (*R,R*)-**3b**




^1H NMR of 1,1'-((4*R*,5*R*)-2,2-dimethyl-1,3-dioxolane-4,5-diyl)bis(3-(dimethylamino)prop-2-en-1-one) ((*R,R*)-**4a**) (CDCl_3)




¹³C NMR of (*R,R*)-4a (CDCl₃)




IR spectrum of (*R,R*)-4a




^1H NMR of 1,1'-((4R,5R)-2,2-dipropyl-1,3-dioxolane-4,5-diyl)bis(3-(dimethylamino)prop-2-en-1-one) (**(R,R)-4b**) (CDCl_3)




^{13}C NMR of **(R,R)-4a** (CDCl_3)




IR spectrum of (*R,R*)-4a




^1H NMR of 3,3'-((4*S*,5*S*)-2,2-dimethyl-1,3-dioxolane-4,5-diyl)bispyrazole ((*S,S*)-5a) (CD_3CN)




¹³C NMR of (S,S)-5a (CD₃OD)




IR spectrum of (*S,S*)-5a




¹H NMR of 3,3'-((4*S*,5*S*)-2,2-dipropyl-1,3-dioxolane-4,5-diyl)bispyrazole ((*S,S*)-5b) (CDCl₃)




¹³C NMR of (*S,S*)-5b (CDCl₃)




IR spectrum of **(S,S)-5b**




^1H NMR of 1,1'-((4*R*,5*R*)-2,2-dimethyl-1,3-dioxolane-4,5-diyl)bis(butan-1,3-dione) ((*R,R*)-**6**) (CDCl_3)




^{13}C NMR of ((*R,R*)-**6**) (CDCl_3)




^1H NMR of 3,3'-((4*S*,5*S*)-2,2-dimethyl-1,3-dioxolane-4,5-diyl)bis(5-methyl-pyrazole) ((***S,S***)-**7**) (CDCl_3)




^{13}C NMR of (***S,S***)-**7** (CDCl_3)




IR spectrum of (*S,S*)-7




^1H NMR of $[\text{Pd}(\eta^3\text{-Allyl})(\text{bpz})]\text{PF}_6$ (**8**) (CDCl_3)







¹H NMR of [(Rh(COD))₂bpz] (**9**) (CDCl₃)




¹³C NMR of complex **9** (CDCl₃)



IR spectrum of complex (9)



3D-Structure of (*S,S*)-**5a** by hydrogen bonds



Remark 1: The absolute configuration of (*S,S*)-**5a** could not be determined by the Flack parameter value but is clear through the synthetic procedure.

Remark 2: In (*S,S*)-**8** the allyl moiety was disordered in two sites. Usual geometrical restraints and restraints on displacement parameters were used to make the final model chemically reasonable. Geometrical restraints SADI were applied to get reasonably equal distances between the Pd centre and the middle carbon atoms of the two sites of the allyl group. The restraints on displacement parameters like SIMU and DELU were used to enable the atoms which are bonding together to move similarly. For C13a, ISOR restraint avoided NPD trend of this atom.

Remark 3: The absolute configuration of **(S,S)-8** was determined by the Flack parameter value.

Remark 4: The absolute configuration of **(S,S)-9** was determined by the Flack parameter value.